WHG
KYMR icon

Westwood Holdings Group’s Kymera Therapeutics KYMR Stock Holding History

Westwood Holdings Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,926
Closed -$618K – 502
2025
Q3 		$618K Buy
+10,926
New +$493K ﹤0.01% 408

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Westwood Holdings Group's KYMR Position: Q4 2025 in Review

Westwood Holdings Group sold out of Kymera Therapeutics (KYMR) in Q4 2025, closing a stake of 10,926 shares — an estimated $618K sold.

Westwood Holdings Group first reported a position in KYMR in Q3 2025 and held it in 1 quarter. The position peaked at $618K in Q3 2025. 254 funds tracked by Wall St. Rank hold KYMR as of Q4 2025.

  • Westwood Holdings Group reported no remaining Kymera Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Westwood Holdings Group sold 10,926 Kymera Therapeutics shares in Q4 2025, an estimated $618K.
  • Westwood Holdings Group first reported a position in Kymera Therapeutics in Q3 2025 and held it in 1 quarter.
  • Westwood Holdings Group's Kymera Therapeutics position peaked at $618K in Q3 2025.
  • 254 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2025.

Based on Westwood Holdings Group's 13F filing for Q4 2025, filed 17 Feb 2026.